Gene · 965
Papers4,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,043
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanical forces impair antigen discrimination by reducing differences in T-cell receptor/peptide-MHC off-rates. | EMBO J | 2023 | 36484367 | PubTator, text mining | PubMed |
| Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. | Transl Oncol | 2023 | 36481605 | PubTator, text mining | PubMed |
| Flagellin-specific human CAR Tregs for immune regulation in IBD. | J Autoimmun | 2023 | 36470208 | PubTator, text mining | PubMed |
| Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia. | Cytometry B Clin Cytom | 2023 | 36433814 | PubTator, text mining | PubMed |
| Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the QuantiFERON SARS-CoV-2 assay. | Pulmonology | 2023 | 36402704 | PubTator, text mining | PubMed |
| Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma. | Mol Diagn Ther | 2023 | 36401148 | PubTator, text mining | PubMed |
| High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia. | Pediatr Blood Cancer | 2023 | 36250996 | PubTator, text mining | PubMed |
| Transformation of FL into DLBCL with a PMBL gene expression signature. | Blood Adv | 2023 | 36240289 | PubTator, text mining | PubMed |
| Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints. | Am J Surg Pathol | 2023 | 36221796 | PubTator, text mining | PubMed |
| Human natural killer cells: Form, function, and development. | J Allergy Clin Immunol | 2023 | 36195172 | PubTator, text mining | PubMed |
| Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment. | J Invest Dermatol | 2023 | 36163302 | PubTator, text mining | PubMed |
| Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination. | Genes Dis | 2023 | 36097543 | PubTator, text mining | PubMed |
| Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer. | Int J Cancer | 2023 | 36054490 | PubTator, text mining | PubMed |
| Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. | Cancer Immunol Immunother | 2023 | 35998004 | PubTator, text mining | PubMed |
| Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL. | Blood Adv | 2023 | 35901280 | PubTator, text mining | PubMed |
| Proteogenomic characterization of cholangiocarcinoma. | Hepatology | 2023 | 35716043 | PubTator, text mining | PubMed |
| PSEUDOPANUVEITIS AS A HARBINGER FOR SYSTEMIC LEUKEMIA RECURRENCE. | Retin Cases Brief Rep | 2023 | 34081042 | PubTator, text mining | PubMed |
| Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL. | Cancer Res Commun | 2022 | 36922932 | PubTator, text mining | PubMed |
| Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report. | Front Oncol | 2022 | 36798689 | PubTator, text mining | PubMed |
| HROP68: A rare case of medullary pancreatic cancer-characterization and chemosensitivity of the first patient-derived cell line. | Front Oncol | 2022 | 36761421 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/965/papers?page=22